Beate Husain1,2, Michael Constantin Kirchberger2,3,4, Michael Erdmann1,3,4, Sabine Schüpferling1,3,4, Amir-Reza Abolhassani5, Waltraud Fröhlich1,3,4, Carola Berking1,3,4, Lucie Heinzerling6,7,8. 1. Department of Dermatology, Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany. 2. Friedrich-Alexander University Erlangen-Nuremberg, 91054, Erlangen, Germany. 3. Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054, Erlangen, Germany. 4. Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany. 5. Department of Cardiology, Klinikum Forchheim, 91301, Forchheim, Germany. 6. Department of Dermatology, Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany. lheinzer@post.harvard.edu. 7. Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054, Erlangen, Germany. lheinzer@post.harvard.edu. 8. Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany. lheinzer@post.harvard.edu.
Abstract
PURPOSE: Immune checkpoint inhibitors (ICI) are highly effective in several cancer entities, but also invoke a variety of immune-related adverse events (irAE). These are mostly reversible, but can be life-threatening or even fatal. Currently, the pathogenesis is not fully understood, but crucial for effective treatment. Prediction and early detection of irAE could be facilitated and treatment optimized if relevant biomarkers and effector mechanisms were better characterized. METHODS: This study included a total of 45 irAE in patients with metastatic melanoma who were treated with ICI. All patients underwent a complete work-up with exclusion of other causes. Longitudinal blood samples were analyzed for a panel of soluble markers and compared to baseline and to patients who did not experience any irAE. Measurements included LDH, interleukin (IL)-6, IL-1β, IL-17, C-reactive protein (CRP) and tumor necrosis factor (TNF)-alpha as well as tumor markers S100 and melanoma inhibitory activity (MIA). RESULTS: During the early onset of irAE increases in serum IL-6 (from mean 24.4 pg/ml at baseline to 51.0 pg/ml; p = 0.003) and CRP (from mean 7.0 mg/l at baseline to 17.7 mg/l; p = 0.001) and a decrease in MIA (from mean 5.4 pg/ml at baseline to 4.8 pg/ml; p = 0.035) were detected. No changes in IL-17 were noted. These effects were observed for irAE of different organ systems. CONCLUSION: Increases of a combination of IL-6 and CRP serum levels can be used for the early detection of irAE and tailored management. Interestingly, changes in MIA serum levels also correlate with irAE onset.
PURPOSE: Immune checkpoint inhibitors (ICI) are highly effective in several cancer entities, but also invoke a variety of immune-related adverse events (irAE). These are mostly reversible, but can be life-threatening or even fatal. Currently, the pathogenesis is not fully understood, but crucial for effective treatment. Prediction and early detection of irAE could be facilitated and treatment optimized if relevant biomarkers and effector mechanisms were better characterized. METHODS: This study included a total of 45 irAE in patients with metastatic melanoma who were treated with ICI. All patients underwent a complete work-up with exclusion of other causes. Longitudinal blood samples were analyzed for a panel of soluble markers and compared to baseline and to patients who did not experience any irAE. Measurements included LDH, interleukin (IL)-6, IL-1β, IL-17, C-reactive protein (CRP) and tumor necrosis factor (TNF)-alpha as well as tumor markers S100 and melanoma inhibitory activity (MIA). RESULTS: During the early onset of irAE increases in serum IL-6 (from mean 24.4 pg/ml at baseline to 51.0 pg/ml; p = 0.003) and CRP (from mean 7.0 mg/l at baseline to 17.7 mg/l; p = 0.001) and a decrease in MIA (from mean 5.4 pg/ml at baseline to 4.8 pg/ml; p = 0.035) were detected. No changes in IL-17 were noted. These effects were observed for irAE of different organ systems. CONCLUSION: Increases of a combination of IL-6 and CRP serum levels can be used for the early detection of irAE and tailored management. Interestingly, changes in MIA serum levels also correlate with irAE onset.
Authors: Laura C Cappelli; Anna Kristina Gutierrez; Alan N Baer; Jemima Albayda; Rebecca L Manno; Uzma Haque; Evan J Lipson; Karen B Bleich; Ami A Shah; Jarushka Naidoo; Julie R Brahmer; Dung Le; Clifton O Bingham Journal: Ann Rheum Dis Date: 2016-06-15 Impact factor: 19.103
Authors: R Dahlén; H Strid; A Lundgren; S Isaksson; S Raghavan; M K Magnusson; M Simrén; H Sjövall; L Öhman Journal: Scand J Immunol Date: 2013-09 Impact factor: 3.487
Authors: Lucie Heinzerling; Patrick A Ott; F Stephen Hodi; Aliya N Husain; Azadeh Tajmir-Riahi; Hussein Tawbi; Matthias Pauschinger; Thomas F Gajewski; Evan J Lipson; Jason J Luke Journal: J Immunother Cancer Date: 2016-08-16 Impact factor: 13.751
Authors: Yousef R Badran; Justine V Cohen; Priscilla K Brastianos; Aparna R Parikh; Theodore S Hong; Michael Dougan Journal: J Immunother Cancer Date: 2019-08-22 Impact factor: 13.751
Authors: Shaheen Khan; Saad A Khan; Xin Luo; Farjana J Fattah; Jessica Saltarski; Yvonne Gloria-McCutchen; Rong Lu; Yang Xie; Quan Li; Edward Wakeland; David E Gerber Journal: Br J Cancer Date: 2018-10-31 Impact factor: 7.640
Authors: Jonas K Kurzhals; Tobias Graf; Katharina Boch; Ulrike Grzyska; Alex Frydrychowicz; Detlef Zillikens; Patrick Terheyden; Ewan A Langan Journal: Front Med (Lausanne) Date: 2021-07-05